Evidence Hub

Clinical outcomes among COVID-19 patients managed with modern and traditional Siddha medicine – A retrospective cohort study

Ramaswamy Meenakumari, Karuppiah Thangaraj, Arunachalam Sundaram, M. Meenakshi Sundaram, Ponnappan Shanmugapriya, A.S. T Mariappan, Melvin George, V. Suba et al.

Journal of Ayurveda and Integrative Medicine, 2021

197 participants · 25 citations

Abstract

BACKGROUND: (KSK) is a Siddha polyherbal decoction recommended by the Ministry of AYUSH and the Tamil Nadu government to prevent and manage COVID-19 in India. OBJECTIVES: We aimed to determine the outcome of integrated therapy for COVID-19 using KSK in virologic clearance and length of hospital stay. MATERIALS AND METHODS: It was a single-centre, retrospective cohort study. We included the COVID-19 patients admitted to SRM Medical College Hospital and Research Centre, Chennai, during May-June 2020. KSK was administered along with the standard of care for all the patients. We collected data pertaining to demographic, clinical, and laboratory parameters and presented as frequencies and proportions. RESULTS: We collected 204 COVID-19 positive patients' data. The mean (SD) age was 39.5 (13.4) years with a range of 13-79. Majority of the patients were male (n = 157; 77%), 28% (n = 58) had any co-morbidities, and 61% (n = 131) had mild symptoms. Fever (n = 57; 27.9%) and cough (n = 53; 25.9%) were the commonly reported symptoms. Paracetamol (n = 135; 66.7%) and Zincovit (n = 197, 96.6%) were the commonly administered medicines along with KSK. About 74% of asymptomatic (n = 54) and 65% of mild symptomatic (n = 85) patients turned negative for COVID-19 in RT-PCR within 4-7 days. There was a significant difference in the blood parameters (p < 0.05) after the integrated treatment. CONCLUSION: The use of KSK with standard care of treatment in COVID-19 treatment had notable results in…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 197 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free